Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) had its price objective reduced by analysts at Citizens Jmp from $166.00 to $160.00 in a research note issued to investors on Friday, Marketbeat reports. The firm currently has a “market outperform” rating on the stock. Citizens Jmp‘s price objective suggests a potential upside of 42.40% from the stock’s previous close.
Several other brokerages also recently commented on RYTM. JPMorgan Chase & Co. dropped their price target on Rhythm Pharmaceuticals from $145.00 to $142.00 and set an “overweight” rating on the stock in a research report on Friday, November 6th. William Blair initiated coverage on Rhythm Pharmaceuticals in a research report on Friday, October 16th. They issued an “outperform” rating for the company. Deutsche Bank assumed coverage on shares of Rhythm Pharmaceuticals in a research note on Friday, August 28th. They issued a “hold” rating and a $120.00 price objective on the stock. Oppenheimer reaffirmed a “market perform” rating on shares of Rhythm Pharmaceuticals in a research report on Wednesday, November 4th. Finally, National Bank Financial set a $160.00 target price on shares of Rhythm Pharmaceuticals in a research report on Wednesday, August 5th. Eighteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Rhythm Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $141.67.
View Our Latest Stock Report on Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Trading Down 3.8%
Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last announced its earnings results on Tuesday, November 3rd. The company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.10. Rhythm Pharmaceuticals had a negative net margin of 69.03% and a negative return on equity of 171.16%. The firm had revenue of $92.13 million for the quarter, compared to the consensus estimate of $85.56 million. During the same quarter last year, the firm posted ($0.82) EPS. The business’s quarterly revenue was up 79.6% on a year-over-year basis. Equities research analysts forecast that Rhythm Pharmaceuticals will post -4.90 EPS for the current fiscal year.
Insider Transactions at Rhythm Pharmaceuticals
In other Rhythm Pharmaceuticals news, CEO David P. Meeker sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $102.67, for a total value of $5,133,500.00. Following the completion of the transaction, the chief executive officer owned 239,258 shares of the company’s stock, valued at $24,564,618.86. This represents a 17.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Hunter C. Smith sold 62,774 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $105.46, for a total value of $6,620,146.04. Following the completion of the sale, the chief financial officer owned 114,024 shares of the company’s stock, valued at $12,024,971.04. This represents a 35.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 168,695 shares of company stock valued at $18,356,174. 5.90% of the stock is currently owned by insiders.
Institutional Trading of Rhythm Pharmaceuticals
Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. acquired a new position in Rhythm Pharmaceuticals in the second quarter worth about $683,601,000. Primecap Management Co. CA bought a new position in Rhythm Pharmaceuticals during the second quarter worth about $351,838,000. Jupiter Topco LLC acquired a new stake in Rhythm Pharmaceuticals during the second quarter valued at approximately $102,752,000. Bank of America Corp DE boosted its holdings in Rhythm Pharmaceuticals by 180.0% during the first quarter. Bank of America Corp DE now owns 628,667 shares of the company’s stock valued at $54,675,000 after purchasing an additional 404,183 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in Rhythm Pharmaceuticals during the second quarter valued at approximately $43,751,000.
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts, and its work centers on the melanocortin-4 receptor pathway, which helps regulate hunger and energy balance. Its commercial product, IMCIVREE (setmelanotide), is approved in the United States and Europe for certain forms of genetically defined obesity, including obesity associated with Bardet-Biedl syndrome and specific gene deficiencies.
Further Reading
- Five stocks we like better than Rhythm Pharmaceuticals
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
